Skip to content

Pain in Patients With Crohn Disease (PAINCD)

Epidemiology and Characterization of Pain in Patients With Crohn Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04488146
Acronym
PAINCD
Enrollment
200
Registered
2020-07-27
Start date
2020-10-31
Completion date
2021-02-28
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Depression, Anxiety, Pain

Keywords

crohn disease, pain

Brief summary

Abdominal pain is a common symptom in patients with Crohn disease (CD). Pain is multifactorial, may result from inflammation but persists in many patients during remission. The aim of our study is to determine the epidemiology of pain in CD patients and define the characteristics of pain : localisation, temporal and sensorial characteristics, neuropathic component, impact on quality of life and mood.

Detailed description

Abdominal pain is a common symptom in patients with inflammatory bowel disease (IBD) that alters quality of life and can lead to increased healthcare utilization. In addition to abdominal pain, pain can result from extra-intestinal manifestation of IBD. 40% of IBD patients suffer from extra-intestinal manifestations. Although abdominal pain has been traditionally attributed to inflammation, functional abdominal pain exists in patients with IBD, associated with a variety of potential causes. About 20-40% of patients in complete clinical and endoscopic remission continue to experience chronic pain. Thus, when examining an IBD patient with abdominal pain, in addition to IBD-related complications (e.g., inflammation, stricture), it is important to screen for other contributors, including peripheral factors (visceral hypersensitivity, bacterial overgrowth, and bowel dysmotility) and centrally mediated neurobiological and psychosocial underpinnings. These central factors include psychological symptoms, sleep disturbance, and stress. Opioid-induced hyperalgesia (e.g., narcotic bowel syndrome) is also growing in recognition as a potential central source of abdominal pain. Pronounced severe pain impacts health related quality of life (QoL). Longstanding pain leads to decreased QoL, increase in pain medication intake, and co-morbidities including depression, anxiety and even addiction. Furthermore, pain attacks severely interfere with social and professional life. Knowledge of these potential aetiologies should be used to individualize treatment of abdominal pain in patients with IBD. Accurate assessment of the source of pain can help guide appropriate diagnosis workup and use of modifying therapy. The aim of the study is to determine the epidemiology of pain in patients with Crohn disease (CD) and to characterize their pain (localisation, temporal characteristics, acute vs. chronic, sensorial characteristics, existence of neuropathic component, existence of hyperalgesia), and their impact of QoL, depression and anxiety

Interventions

None listed

Sponsors

University of Liege
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* any patient with Crohn disease in remission or relapse period age ≥ 18 yo.

Exclusion criteria

* No

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity in patients with Crohn Disease (CD)During the last 30 daysPain intensity measured using a 100 mm visual analog scale (0 = no pain; 100 the worst imaginable pain)

Secondary

MeasureTime frameDescription
Presence of hyperalgesiaDuring the last 30 daysUsing Von Frey hairs (size 2.83 for dectection of allodynia; size 6.65 for temporal somation)
Search for a neuropathic component of painDuring the last 30 daysUsing DN-4 questionnaires : a score ≥ 3 = neuropathic component
Investigation of the impact of pain on depression and anxieteyDuring the last 30 daysUsing the HAD (Hospital anxiety depression) scale : as score \> 11 = true symptomatology

Contacts

Primary ContactJean L Joris, M.D.
jean.joris@chuliege.be+32-4-3667180
Backup ContactPierre-Yves Hardy, M.D
pyhardy@student.uliege.be+32-4-3667180

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026